Biotech Values

[DewDiligence]

With ABBV earnings/guidance out friday morning, there should be more clarity soon.

Maybe. 4Q14 results will be meaningless, so the question is how much granularity ABBV provides in its 2015 guidance for HCV sales. ABBV may say that it’s still too early in the V-Pak launch to provide the kind of granularity that some investors might be expecting, and hence we may not find out how well V-Pak is selling until ABBV reports 1Q15 financial results in April.

Biotech investing requires patience!